XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
2. Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Fair Value Disclosures [Abstract]    
Debt Securities, Available-for-sale [Table Text Block]
Available-for-sale investments consist of the following (in millions):
 March 31, 2022
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Allowances for Credit Losses
Fair
Value
Short-term investments:    
Corporate debt securities$579.1 $0.2 $(2.6)$— $576.7 
Municipal obligations34.8 — (0.1)— 34.7 
Asset-backed securities$331.9 $0.1 $(1.6)$— $330.4 
U.S. government sponsored agencies255.2 — (0.9)— 254.3 
Foreign government obligations$1.5 $— $— $— $1.5 
Certificates of Deposit8.0 — — — 8.0 
 $1,210.5 $0.3 $(5.2)$— $1,205.6 
Available-for-sale investments consist of the following (in millions):
 December 31, 2021
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Allowances for Credit LossesEstimated
Fair
Value
Short-term investments:    
Corporate debt securities$181.9 $0.5 $(0.2)— $182.2 
Municipal obligations9.0 — — — 9.0 
Asset-backed securities87.5 0.1 (0.2)— 87.4 
U.S. government sponsored agencies44.3 — — — 44.3 
Foreign government obligations1.0 — — — 1.0 
  Other foreign obligations3.8 — — — 3.8 
Total327.5 0.6 (0.4)— 327.7 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Level 2 Fair Value Measurements

To estimate the fair value of Level 2 debt securities as of March 31, 2022, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.

Available-for-sale investments consist of the following (in millions):
 March 31, 2022
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Allowances for Credit Losses
Fair
Value
Short-term investments:    
Corporate debt securities$579.1 $0.2 $(2.6)$— $576.7 
Municipal obligations34.8 — (0.1)— 34.7 
Asset-backed securities$331.9 $0.1 $(1.6)$— $330.4 
U.S. government sponsored agencies255.2 — (0.9)— 254.3 
Foreign government obligations$1.5 $— $— $— $1.5 
Certificates of Deposit8.0 — — — 8.0 
 $1,210.5 $0.3 $(5.2)$— $1,205.6 

The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2022 by contractual maturity date (in millions):
Amortized
Cost		Estimated Fair
Value
Mature in less than one year$519.2 $518.3 
Mature in one to five years556.2 552.8 
Mature in more than five years135.1 134.5 
Total$1,210.5 $1,205.6 

Available-for-sale investments consist of the following (in millions):
 December 31, 2021
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Allowances for Credit LossesEstimated
Fair
Value
Short-term investments:    
Corporate debt securities$181.9 $0.5 $(0.2)— $182.2 
Municipal obligations9.0 — — — 9.0 
Asset-backed securities87.5 0.1 (0.2)— 87.4 
U.S. government sponsored agencies44.3 — — — 44.3 
Foreign government obligations1.0 — — — 1.0 
  Other foreign obligations3.8 — — — 3.8 
Total327.5 0.6 (0.4)— 327.7 

There were no significant unrealized losses as of March 31, 2022 and December 31, 2021 in either the less than or greater than 12 month categories.
Our evaluation of credit losses for available-for-sale debt securities included the extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis.

At March 31, 2022, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of March 31, 2022.
Included in other current assets are $6.6 million and $2.2 million of interest receivable as of March 31, 2022 and December 31, 2021, respectively, primarily associated with securities in our available-for-sale investments portfolio. The interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the three months ended March 31, 2022, we have not written-off any uncollected interest receivable.
As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date. The notional principal amounts provide one measure of the transaction volume outstanding as of March 31, 2022 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Refinitiv on the last business day of the quarter and the points provided by counterparties. The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign currency exchange (gains) losses, net in the condensed consolidated statements of income (loss).

The following is a summary of our forward foreign exchange contracts (in millions):
 March 31,
 2022
Contracts maturing in April through June 2022 to sell foreign currency: 
Notional value$85.6 
Unrealized gain/(loss)$(0.2)
Contracts maturing in April through June 2022 to purchase foreign currency: 
Notional value$513.5 
Unrealized gain/(loss)$(3.8)
  
Discussion of current derivative risk management
The following is a summary of our forward foreign exchange contracts (in millions):
 March 31,
 2022
Contracts maturing in April through June 2022 to sell foreign currency: 
Notional value$85.6 
Unrealized gain/(loss)$(0.2)
Contracts maturing in April through June 2022 to purchase foreign currency: 
Notional value$513.5 
Unrealized gain/(loss)$(3.8)
  
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2022 by contractual maturity date (in millions):
Amortized
Cost		Estimated Fair
Value
Mature in less than one year$519.2 $518.3 
Mature in one to five years556.2 552.8 
Mature in more than five years135.1 134.5 
Total$1,210.5 $1,205.6 
  
Fair Value Measurements, Recurring and Nonrecurring
Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2022 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $201.6 $— $201.6 
Time deposits21.0 10.0 — 31.0 
Asset-backed securities— 5.5 — 5.5 
Foreign government obligations— 8.0 — 8.0 
Municipals obligations— 9.9 9.9 
U.S. government sponsored agencies— 71.2 — 71.2 
Money market funds101.6 — — 101.6 
Total cash equivalents (a)122.6 306.2 — 428.8 
Restricted investments (b)6.9 — — 6.9 
Equity securities (c)9,371.2 — — 9,371.2 
Loan under the fair value option (d)— — 342.6 342.6 
Available-for-sale investments:
Corporate debt securities— 576.7 — 576.7 
U.S. government sponsored agencies— 254.3 — 254.3 
Foreign government obligations— 1.5 — 1.5 
Certificates of deposit— 8.0 — 8.0 
Municipal obligations— 34.7 — 34.7 
Asset-backed securities— 330.4 — 330.4 
Total available-for-sale investments (e)— 1,205.6 — 1,205.6 
Forward foreign exchange contracts (f)— 0.4 — 0.4 
Total financial assets carried at fair value$9,500.7 $1,512.2 $342.6 $11,355.5 
Financial liabilities carried at fair value:   
Forward foreign exchange contracts (g)$— $4.4 $— $4.4 
Total financial liabilities carried at fair value$— $4.4 $— $4.4 
Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2021 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $39.8 $— $39.8 
Time deposits7.2 10.1 — 17.3 
Asset-backed securities— 0.1 — 0.1 
Foreign government obligations— 0.8 — 0.8 
Municipals obligations— 0.3 0.3 
U.S. government sponsored agencies— 33.6— 33.6 
Money market funds50.7 — — 50.7 
Total cash equivalents (a)57.9 84.7 — 142.6 
Restricted investments (b)6.9 — — 6.9 
Equity securities (c)13,977.5 — — 13,977.5 
Loan under the fair value option (d)— — 443.1 443.1 
Available-for-sale investments:
Corporate debt securities— 182.3 — 182.3 
U.S. government sponsored agencies— 44.3 — 44.3 
Foreign government obligations— 1.0 — 1.0 
Other foreign obligations— 3.8 — 3.8 
Municipal obligations— 9.0 — 9.0 
Asset-backed securities— 87.3 — 87.3 
Total available-for-sale investments (e)— 327.7 — 327.7 
Forward foreign exchange contracts (f)— 1.7 — 1.7 
Total financial assets carried at fair value$14,042.3 $414.1 $443.1 $14,899.5 
Financial liabilities carried at fair value:
Forward foreign exchange contracts (g)$— $2.8 $— $2.8 
Total financial liabilities carried at fair value$— $2.8 $— $2.8 

(a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.

(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2022December 31, 2021
Restricted investments$5.6 $5.6 
Other investments1.3 1.3 
    Total$6.9 $6.9 

(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2022December 31, 2021
Short-term investments$65.6 $71.4 
Other investments9,305.6 13,906.1 
        Total$9,371.2 $13,977.5 
(d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets.

(e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.

(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.

(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.

Level 1 Fair Value Measurements

As of March 31, 2022, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 37% of the ordinary outstanding shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of March 31, 2022. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting.

The changes in fair market value of our investment in Sartorius for the three months ended March 31, 2022 was $4.45 billion loss and is recorded in our condensed consolidated statements of income (loss).